|Title:||Availability of Rituximab for Approved Indications|
|Document ID:||Operational Circular OP 1751/04|
|Date of issue:||Thursday, 18 March 2004|
|Status:||NO LONGER APPLICABLE|
|Description:||The Western Australian Therapeutic Advisory Group (WATAG) recommends that rituximab (Mabthera®) should be listed on the formularies of public hospitals for use in the following approved indications, subject to the same restrictions as under the PBS, plus additional criteria for public hospital use:
|Applicable to:||Clinicians, pharmacists and managers|
|Period of effect:||from 4 March 2004|
|Authorised by:||Dr Andrew Robertson, Director, Clinical Policy and Programs, 14-Mar-2004|
|Print version:||View print version|
Availability of Rituximab for Approved Indications
Upon the recommendation of the Westen Australian Therapeutic Advisory Group (WATAG), the Department of Health has resolved that:
Rituximab (Mabthera®) shall be listed on the formularies of public hospitals (where specialist services are provided) for use in the following approved indications.
Use of rituximab in public hospitals for both these indications is subject to the same restrictions as under the Pharmaceutical Benefits Scheme (PBS), plus additional criteria for public hospital use.
ADDITIONAL CRITERIA (indication 2 only)
Further to the PBS requirements, two additional sets of criteria shall apply to public hospital use of rituximab for relapse or refractory, low grade or follicular B-cell non-Hodgkin's lymphoma (indication 2, above). These additional criteria shall determine eligibility for initiation of therapy and for stopping the drug when responsiveness to it is lost. Accordingly, patients must satisfy the following:
In addition to PBS requirements, hospital clinicians and pharmacies shall monitor and report their use of rituximab, and this information will be subject to independent clinical audit on the use of rituximab in accordance with the criteria detailed in this Operational Circular.
Dr Andrew Robertson
This circular last updated: Thursday, 18 March 2004 at 12:00am